|
Dr. Cohen is a partner at TPG, where he initiated their investment efforts in the life sciences forming TPG Biotechnology. He also retains a position as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. He also serves as a member of the boards of GenomicHealth, XDx, Kemia, CardioDx, Anaborex, Quintiles Transnational, Five Prime Therapeutics, and Matrix Laboratories. He received his M.D. from Stanford, his D.Phil. in Molecular Biophysics from Oxford as a Rhodes Scholar and his Bachelor’s degree from Yale University in Molecular Biophysics and Biochemistry. Dr. Cohen has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease. He is a member of the Institute of Medicine of the National Academy of Sciences.] | 